Logo image of VALN

VALNEVA SE - ADR (VALN) Stock Fundamental Analysis

USA - NASDAQ:VALN - US92025Y1038 - ADR

9.8 USD
-0.07 (-0.71%)
Last: 10/22/2025, 8:07:04 PM
Fundamental Rating

3

VALN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. VALN has a bad profitability rating. Also its financial health evaluation is rather negative. VALN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year VALN has reported negative net income.
In the past year VALN has reported a negative cash flow from operations.
In the past 5 years VALN always reported negative net income.
In multiple years VALN reported negative operating cash flow during the last 5 years.
VALN Yearly Net Income VS EBIT VS OCF VS FCFVALN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

VALN has a Return On Assets of -18.09%. This is in the better half of the industry: VALN outperforms 78.46% of its industry peers.
With a decent Return On Equity value of -45.87%, VALN is doing good in the industry, outperforming 68.54% of the companies in the same industry.
Industry RankSector Rank
ROA -18.09%
ROE -45.87%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
VALN Yearly ROA, ROE, ROICVALN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

VALN's Gross Margin of 48.94% is fine compared to the rest of the industry. VALN outperforms 75.28% of its industry peers.
VALN's Gross Margin has declined in the last couple of years.
VALN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
VALN Yearly Profit, Operating, Gross MarginsVALN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

3

2. Health

2.1 Basic Checks

VALN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VALN has more shares outstanding
The number of shares outstanding for VALN has been increased compared to 5 years ago.
The debt/assets ratio for VALN has been reduced compared to a year ago.
VALN Yearly Shares OutstandingVALN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VALN Yearly Total Debt VS Total AssetsVALN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 0.57, we must say that VALN is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.57, VALN is doing good in the industry, outperforming 60.30% of the companies in the same industry.
A Debt/Equity ratio of 0.80 indicates that VALN is somewhat dependend on debt financing.
The Debt to Equity ratio of VALN (0.80) is worse than 74.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF N/A
Altman-Z 0.57
ROIC/WACCN/A
WACC8%
VALN Yearly LT Debt VS Equity VS FCFVALN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 2.27 indicates that VALN has no problem at all paying its short term obligations.
The Current ratio of VALN (2.27) is worse than 71.35% of its industry peers.
A Quick Ratio of 1.77 indicates that VALN should not have too much problems paying its short term obligations.
VALN's Quick ratio of 1.77 is on the low side compared to the rest of the industry. VALN is outperformed by 77.34% of its industry peers.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 1.77
VALN Yearly Current Assets VS Current LiabilitesVALN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

VALN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -95.65%.
VALN shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.49%.
The Revenue has been growing slightly by 6.09% on average over the past years.
EPS 1Y (TTM)-95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
Revenue 1Y (TTM)31.49%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%26.98%

3.2 Future

The Earnings Per Share is expected to grow by 53.87% on average over the next years. This is a very strong growth
VALN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.97% yearly.
EPS Next Y-580.55%
EPS Next 2Y-96.15%
EPS Next 3Y120.41%
EPS Next 5Y53.87%
Revenue Next Year4.16%
Revenue Next 2Y12.8%
Revenue Next 3Y28.76%
Revenue Next 5Y17.97%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VALN Yearly Revenue VS EstimatesVALN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
VALN Yearly EPS VS EstimatesVALN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VALN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VALN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VALN Price Earnings VS Forward Price EarningsVALN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VALN Per share dataVALN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as VALN's earnings are expected to grow with 120.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-96.15%
EPS Next 3Y120.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VALN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALNEVA SE - ADR

NASDAQ:VALN (10/22/2025, 8:07:04 PM)

9.8

-0.07 (-0.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-13 2025-11-13
Inst Owners22.62%
Inst Owner Change0.02%
Ins Owners0.22%
Ins Owner ChangeN/A
Market Cap841.48M
Revenue(TTM)291.38M
Net Income(TTM)-85509000
Analysts84
Price Target16.08 (64.08%)
Short Float %0.02%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.78%
Min EPS beat(2)56.68%
Max EPS beat(2)62.87%
EPS beat(4)3
Avg EPS beat(4)14.13%
Min EPS beat(4)-115.24%
Max EPS beat(4)62.87%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)-23.48%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)21.69%
Min Revenue beat(2)16.4%
Max Revenue beat(2)26.97%
Revenue beat(4)3
Avg Revenue beat(4)10.09%
Min Revenue beat(4)-4.78%
Max Revenue beat(4)26.97%
Revenue beat(8)4
Avg Revenue beat(8)1.3%
Revenue beat(12)7
Avg Revenue beat(12)19.63%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.03%
PT rev (3m)-3.22%
EPS NQ rev (1m)10.87%
EPS NQ rev (3m)22.7%
EPS NY rev (1m)5%
EPS NY rev (3m)-0.58%
Revenue NQ rev (1m)-0.71%
Revenue NQ rev (3m)-2.09%
Revenue NY rev (1m)0.81%
Revenue NY rev (3m)-2.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.49
P/FCF N/A
P/OCF N/A
P/B 3.9
P/tB 4.47
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS3.93
BVpS2.52
TBVpS2.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.09%
ROE -45.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.94%
FCFM N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score4
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 71.71%
Cap/Sales 5.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 1.77
Altman-Z 0.57
F-Score4
WACC8%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.25%
EPS Next Y-580.55%
EPS Next 2Y-96.15%
EPS Next 3Y120.41%
EPS Next 5Y53.87%
Revenue 1Y (TTM)31.49%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%26.98%
Revenue Next Year4.16%
Revenue Next 2Y12.8%
Revenue Next 3Y28.76%
Revenue Next 5Y17.97%
EBIT growth 1Y-49.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-280.12%
EBIT Next 3Y59.13%
EBIT Next 5Y30.38%
FCF growth 1Y88.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.27%
OCF growth 3YN/A
OCF growth 5YN/A